A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

Adelaide newsreader Will McDonald has managed his aggressive stage 4 prostate cancer for six years now, although he knows the intensive drug regime he is on, while doing the trick for now, won’t last ...

Thirty-six progressive mCRPC patients received TLX591-Tx across three cohorts (enzalutamide, abiraterone, or docetaxel sequence), and all completed two planned doses without emergent, unexpected ...

Clarity Pharmaceuticals (ASX: CU6) (Clarity or Company), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients ...

Leerink Global Healthcare Conference 2026 March 10, 2026 2:20 PM EDTCompany ParticipantsBrian Sullivan - Co-Founder, Chairman ...

A US patent describing a potential cancer treatment is drawing renewed attention after a CIA document resurfaced describing similar research more than 60 years ago.

Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled ...

An important clinical trial announcement is good news for this healthcare stock. The post Bell Potter is tipping this exciting ASX healthcare stock to rise 80% appeared first on The Motley Fool ...

During the Miami Breast Cancer Conference, CURE discussed ADCs with Dr. Kevin Kalinsky. The treatment landscape for breast cancer is shifting rapidly, driven by the rise of antibody-drug conjugates ...

Oral TYK2 inhibitor deucravacitinib receives FDA approval for active psoriatic arthritis based on significantly improved ACR20 response rates.